Compass Pathways (STU:5Y6) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5Y6 Compass Pathways PLC STU:5Y6
37 GF Score
Price €13.20
! 2 Warning Signs
View Full Analysis

What is Compass Pathways Net Loan?

Net Loan only applies to banks and insurance companies.

STU:5Y6
37GF Score
Compass Pathways PLC STU:5Y6
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Pathways Business Description

Other Exchanges CMPS:USACMPSN:Mexico
Address 33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a biotechnology company based in London, United Kingdom, focused on developing psychedelic-based therapies for mental health conditions. Its lead candidate is COMP360, a proprietary synthetic psilocybin formulation administered in conjunction with psychological support. The company is evaluating COMP360 in clinical trials, most notably for treatment-resistant depression, with additional research programs in other mental health indications such as post-traumatic stress disorder and anorexia nervosa. Compass Pathways operates as a single reporting segment and generates no product revenue, funding its operations primarily through equity offerings, collaborations, and grant support. Its activities span clinical development, manufacturing of its synthetic psilocybin, and the training of therapists who deliver psychological support alongside treatment. The company conducts trials across sites in North America, Europe, and other regions, and it has pursued regulatory pathways including the FDA's breakthrough therapy designation for COMP360 in treatment-resistant depression.
37GF Score

Get the complete analysis for STU:5Y6

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.20
Price